Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:52:03 UTC |
---|
HMDB ID | HMDB0015641 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Dabigatran etexilate |
---|
Description | Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. |
---|
Structure | CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1 InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44) |
---|
Synonyms | Value | Source |
---|
Pradaxa | Kegg | Dabigatran etexilic acid | Generator | Dabigatran | HMDB | Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate | HMDB | Etexilate mesylate, dabigatran | HMDB | Etexilate, dabigatran | HMDB | BIBR 1048 | HMDB | Mesylate, dabigatran etexilate | HMDB | N-((2-(((4-(Aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine | HMDB | Dabigatran etexilate mesylate | HMDB |
|
---|
Chemical Formula | C34H41N7O5 |
---|
Average Molecular Weight | 627.7332 |
---|
Monoisotopic Molecular Weight | 627.316917457 |
---|
IUPAC Name | ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate |
---|
Traditional Name | dabigatran etexilate |
---|
CAS Registry Number | 211915-06-9 |
---|
SMILES | CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1 |
---|
InChI Identifier | InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44) |
---|
InChI Key | KSGXQBZTULBEEQ-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds). |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzimidazoles |
---|
Sub Class | Not Available |
---|
Direct Parent | Benzimidazoles |
---|
Alternative Parents | |
---|
Substituents | - Benzimidazole
- Aniline or substituted anilines
- Phenylalkylamine
- Secondary aliphatic/aromatic amine
- Aralkylamine
- Monocyclic benzene moiety
- N-substituted imidazole
- Pyridine
- Benzenoid
- Imidolactam
- Azole
- Imidazole
- Tertiary carboxylic acid amide
- Heteroaromatic compound
- Carboxylic acid ester
- Carboxamide group
- Carbonic acid derivative
- Amino acid or derivatives
- Monocarboxylic acid or derivatives
- Amidine
- Carboxylic acid amidine
- Organic 1,3-dipolar compound
- Carboxylic acid derivative
- Azacycle
- Secondary amine
- Propargyl-type 1,3-dipolar organic compound
- Carboximidamide
- Organic oxygen compound
- Amine
- Organonitrogen compound
- Carbonyl group
- Organic nitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 180 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | 3.8 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Dabigatran etexilate,1TMS,isomer #1 | CCCCCCOC(=O)N=C(N[Si](C)(C)C)C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1 | 5514.7 | Semi standard non polar | 33892256 | Dabigatran etexilate,1TMS,isomer #1 | CCCCCCOC(=O)N=C(N[Si](C)(C)C)C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1 | 4497.6 | Standard non polar | 33892256 | Dabigatran etexilate,1TMS,isomer #1 | CCCCCCOC(=O)N=C(N[Si](C)(C)C)C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1 | 7254.9 | Standard polar | 33892256 | Dabigatran etexilate,1TMS,isomer #2 | CCCCCCOC(=O)N=C(N)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1 | 5258.7 | Semi standard non polar | 33892256 | Dabigatran etexilate,1TMS,isomer #2 | CCCCCCOC(=O)N=C(N)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1 | 4362.4 | Standard non polar | 33892256 | Dabigatran etexilate,1TMS,isomer #2 | CCCCCCOC(=O)N=C(N)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1 | 7466.8 | Standard polar | 33892256 | Dabigatran etexilate,2TMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1)N([Si](C)(C)C)[Si](C)(C)C | 5385.6 | Semi standard non polar | 33892256 | Dabigatran etexilate,2TMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1)N([Si](C)(C)C)[Si](C)(C)C | 4403.1 | Standard non polar | 33892256 | Dabigatran etexilate,2TMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1)N([Si](C)(C)C)[Si](C)(C)C | 6925.3 | Standard polar | 33892256 | Dabigatran etexilate,2TMS,isomer #2 | CCCCCCOC(=O)N=C(N[Si](C)(C)C)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1 | 5322.8 | Semi standard non polar | 33892256 | Dabigatran etexilate,2TMS,isomer #2 | CCCCCCOC(=O)N=C(N[Si](C)(C)C)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1 | 4320.0 | Standard non polar | 33892256 | Dabigatran etexilate,2TMS,isomer #2 | CCCCCCOC(=O)N=C(N[Si](C)(C)C)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1 | 6732.6 | Standard polar | 33892256 | Dabigatran etexilate,3TMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1)N([Si](C)(C)C)[Si](C)(C)C | 5218.7 | Semi standard non polar | 33892256 | Dabigatran etexilate,3TMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1)N([Si](C)(C)C)[Si](C)(C)C | 4204.1 | Standard non polar | 33892256 | Dabigatran etexilate,3TMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C)C=C1)N([Si](C)(C)C)[Si](C)(C)C | 6435.7 | Standard polar | 33892256 | Dabigatran etexilate,1TBDMS,isomer #1 | CCCCCCOC(=O)N=C(N[Si](C)(C)C(C)(C)C)C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1 | 5670.6 | Semi standard non polar | 33892256 | Dabigatran etexilate,1TBDMS,isomer #1 | CCCCCCOC(=O)N=C(N[Si](C)(C)C(C)(C)C)C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1 | 4617.3 | Standard non polar | 33892256 | Dabigatran etexilate,1TBDMS,isomer #1 | CCCCCCOC(=O)N=C(N[Si](C)(C)C(C)(C)C)C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1 | 7162.7 | Standard polar | 33892256 | Dabigatran etexilate,1TBDMS,isomer #2 | CCCCCCOC(=O)N=C(N)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C(C)(C)C)C=C1 | 5450.1 | Semi standard non polar | 33892256 | Dabigatran etexilate,1TBDMS,isomer #2 | CCCCCCOC(=O)N=C(N)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C(C)(C)C)C=C1 | 4444.6 | Standard non polar | 33892256 | Dabigatran etexilate,1TBDMS,isomer #2 | CCCCCCOC(=O)N=C(N)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C(C)(C)C)C=C1 | 7435.3 | Standard polar | 33892256 | Dabigatran etexilate,2TBDMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 5667.1 | Semi standard non polar | 33892256 | Dabigatran etexilate,2TBDMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4645.0 | Standard non polar | 33892256 | Dabigatran etexilate,2TBDMS,isomer #1 | CCCCCCOC(=O)N=C(C1=CC=C(NCC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)C=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 6793.9 | Standard polar | 33892256 | Dabigatran etexilate,2TBDMS,isomer #2 | CCCCCCOC(=O)N=C(N[Si](C)(C)C(C)(C)C)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C(C)(C)C)C=C1 | 5590.0 | Semi standard non polar | 33892256 | Dabigatran etexilate,2TBDMS,isomer #2 | CCCCCCOC(=O)N=C(N[Si](C)(C)C(C)(C)C)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C(C)(C)C)C=C1 | 4528.5 | Standard non polar | 33892256 | Dabigatran etexilate,2TBDMS,isomer #2 | CCCCCCOC(=O)N=C(N[Si](C)(C)C(C)(C)C)C1=CC=C(N(CC2=NC3=CC(C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)=CC=C3N2C)[Si](C)(C)C(C)(C)C)C=C1 | 6683.4 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Dabigatran etexilate GC-MS (Non-derivatized) - 70eV, Positive | splash10-001v-3234390000-c2177c303cbef52afbdf | 2017-09-01 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Dabigatran etexilate LC-ESI-qTof , Positive-QTOF | splash10-004r-0292116000-55b368cbe92da888e681 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dabigatran etexilate , positive-QTOF | splash10-00kk-0981100000-78856b63936cf67ebce2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dabigatran etexilate , positive-QTOF | splash10-004r-0292116000-55b368cbe92da888e681 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 10V, Positive-QTOF | splash10-0ufs-4720194000-b25f304a4eefb48ffb14 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 20V, Positive-QTOF | splash10-0uds-9634660000-7ac6e0cd9b01e5cd8430 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 40V, Positive-QTOF | splash10-0fba-4942200000-823214c2258288f41cbb | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 10V, Negative-QTOF | splash10-00e9-2200592000-91bb2cde7f5a1c074cff | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 20V, Negative-QTOF | splash10-008d-3500940000-5f6725f159c9fa1d9ac1 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 40V, Negative-QTOF | splash10-0007-4504930000-e756884bbf82c6cfced2 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 10V, Positive-QTOF | splash10-004i-0000019000-b01a3a5bf142faf27699 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 20V, Positive-QTOF | splash10-004l-0001960000-f016ad334f1f10cd9561 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 40V, Positive-QTOF | splash10-005i-3913404000-8193e59d4a4ff6967cd9 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 10V, Negative-QTOF | splash10-004i-0000259000-c2af6ee3f89a87dfae64 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 20V, Negative-QTOF | splash10-004i-1000921000-06293e9a87d653604565 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dabigatran etexilate 40V, Negative-QTOF | splash10-0fk9-1001900000-49277b2224b211f8de10 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028-40. [PubMed:16148288 ]
- Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 Jan;3(1):103-11. [PubMed:15634273 ]
- Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 May;45(5):555-63. [PubMed:15831779 ]
- Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85. [PubMed:17764540 ]
- Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. [PubMed:17869635 ]
- Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 Nov 1;100(9):1419-26. Epub 2007 Aug 17. [PubMed:17950801 ]
- Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14. [PubMed:18534438 ]
- Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan;101(1):77-85. [PubMed:19132192 ]
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. [PubMed:19717844 ]
- Bauer KA: New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;7(1):1-8. [PubMed:20410856 ]
- Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752 ]
- European Medicines Agency [Link]
- Abrams P and Marzella N: Dabigatran (Rendix): A Promising New Oral Direct Thrombin Inhibitor. Drug Forecast. 2007;32(5):271-5. [Link]
|
---|